Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to -$1.2 million.

  • Alaunos Therapeutics' Net Income towards Common Stockholders fell 321.74% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year increase of 6607.81%. This contributed to the annual value of -$4.8 million for FY2024, which is 8670.28% up from last year.
  • Latest data reveals that Alaunos Therapeutics reported Net Income towards Common Stockholders of -$1.2 million as of Q3 2025, which was down 321.74% from -$1.0 million recorded in Q2 2025.
  • In the past 5 years, Alaunos Therapeutics' Net Income towards Common Stockholders registered a high of -$755000.0 during Q4 2024, and its lowest value of -$22.7 million during Q3 2021.
  • For the 5-year period, Alaunos Therapeutics' Net Income towards Common Stockholders averaged around -$7.8 million, with its median value being -$8.9 million (2023).
  • Per our database at Business Quant, Alaunos Therapeutics' Net Income towards Common Stockholders crashed by 15348.83% in 2021 and then surged by 9050.19% in 2024.
  • Over the past 5 years, Alaunos Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$11.8 million in 2021, then increased by 20.21% to -$9.4 million in 2022, then increased by 15.62% to -$7.9 million in 2023, then surged by 90.5% to -$755000.0 in 2024, then plummeted by 57.22% to -$1.2 million in 2025.
  • Its Net Income towards Common Stockholders was -$1.2 million in Q3 2025, compared to -$1.0 million in Q2 2025 and -$1.1 million in Q1 2025.